The C-Terminal TDP-43 Fragments Have a High Aggregation Propensity and Harm Neurons by a Dominant-Negative Mechanism by Yang, Chunxing et al.
The C-Terminal TDP-43 Fragments Have a High
Aggregation Propensity and Harm Neurons by a
Dominant-Negative Mechanism
Chunxing Yang
1, Weijia Tan
1, Catheryne Whittle
2, Linghua Qiu
1, Lucheng Cao
1, Schahram Akbarian
2,
Zuoshang Xu
1,3,4*
1Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 2Brudnick
Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America,
3Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 4Neuroscience Program, University of
Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
TAR DNA binding protein 43 KD (TDP-43) is an essential gene that regulates gene transcription, mRNA splicing and stability.
In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two fatal neurodegenerative diseases, TDP-43 is
fragmented, generating multiple fragments that include the C-terminal fragment of ,25 KD. The role of these fragments in
the pathogenesis of ALS and FTD is not clear. Here we investigated the aggregation propensity in various polypeptide
regions of TDP-43 in mammalian cells and the effect of these fragments on cultured neurons. By expressing the full length
and various TDP-43 fragments in motor neuron-derived NSC-34 cells and primary neurons, we found that both N- and C-
terminal fragments of TDP-43 are prone to aggregate and the C-terminal end of RRM2 region is required, though not
sufficient, for aggregation. The aggregation of the TDP-43 fragments can drive co-aggregation with the full-length TDP-43,
consequently reducing the nuclear TDP-43. In addition, the TDP-43 fragments can impair neurite growth during neuronal
differentiation. Importantly, overexpression of the full-length TDP-43 rescues the neurite growth phenotype whereas
knockdown of the endogenous TDP-43 reproduces this phenotype. These results suggest that TDP-43 fragments,
particularly the pathologically relevant C-terminal fragments, can impair neuronal differentiation by dominant-negatively
interfering with the function of the full length TDP-43, thus playing a role in pathogenesis in ALS and FTD.
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Introduction
TAR DNA binding protein-43 (TDP-43) has been identified as
a major component of the ubiquitin-positive protein inclusions in
neurons and glia in ALS, FTD as well as several other
neurodegenerative disorders [1]. TDP-43 is a highly conserved,
non-redundant gene in metazoan species [2] and is an essential
gene because its deletion leads to embryonic lethality [3,4,5].
TDP-43 has two RNA binding motifs, RRM1 and RRM2, and
binds RNA and numerous other proteins to form one or multiple
high molecular weight protein RNA complexes [6,7,8]. As an
abundant nuclear protein [9], TDP-43 regulates gene expression
by modulating transcription, splicing and stability of mRNA
[10,11,12,13,14,15]. TDP-43 is also present in granular structures
in the cytoplasm and may be involved in RNA transport and stress
response [6,16,17].
In both ALS and FTD, TDP-43 is fragmented, resulting in
lower molecular weight C-terminal fragments of ,35 to ,25 KD
[18]. The C-terminal fragments are prominent in the inclusions in
FTD brains and in the insoluble protein fractions from the affected
CNS areas of ALS and FTD [18,19]. These fragments are
phosphorylated at serine 409 and 410 and antibodies against this
phosphorylation epitope is used as an excellent marker for
visualizing TDP-43 inclusions [20]. Recently, these features are
reproduced in several in vitro experiments [21,22,23] and in
transgenic mice that overexpress TDP-43 and display neurode-
generative phenotypes [24,25,26,27]. Despite its potential role in
the pathogenesis of ALS and FTD, neither the mechanism
whereby the C-terminal fragment is produced nor its effect on cells
is clear. The C-terminal fragments may be produced from
proteolytic cleavage by caspases [28], although some cleaved
fragments from patients do not match the caspase consensus
cleavage sites [29,30]. Progranulin deficiency may stimulate the
production of the C-terminal fragments [28] but this remains to be
replicated [31]. Expression of the C-terminal fragments in cultured
cells generally reproduces the aggregation and phosphorylation
[22,23,31]. However, the pathological role of the C-terminal
fragments remains unclear.
To further understand the aggregation propensity of TDP-43
and the role of TDP-43 fragments in pathogenesis, we engineered
a series of TDP-43 truncation fragments and expressed these
fragments in cultured neurons. We found that both the C-terminal
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15878and the N-terminal fragments of TDP-43 can form aggregates as
long as they contain the C-terminal end of the RRM2, which is
necessary but by itself is insufficient for aggregation. The
aggregation of the TDP-43 fragments can drive co-aggregate with
the full-length TDP-43, thereby reducing nuclear TDP-43.
Furthermore, the aggregation-prone fragments can impair neurite
growth during neuronal differentiation. Importantly, this impair-
ment can be rescued by an overexpression of full-length TDP-43
and can be reproduced by a knockdown of the endogenous TDP-
43 expression. These results suggest a model where the C-terminal
fragments of TDP-43, found in ALS and FTD patients, harm
neurons by a dominant-negative mechanism.
Results
Many TDP-43 fragments are prone to aggregate when
expressed in mammalian cells
To understand the properties of fragmented TDP-43, we made
a series of constructs that synthesize the N-terminal and C-
terminal truncated TDP-43 fragments (Fig. 1). We tagged the
constructs with EGFP at their carboxyl termini so that we can
easily follow the behavior of the proteins synthesized from these
constructs. After transfection into motor neuron-like NSC-34 cells
[32], we observed intracellular aggregates from several TDP-43
fragments (Fig. 2A). We quantified the percentage of aggregate-
containing cells among the GFP-fluorescent cells and also the
percentage of cells with aggregates in the nucleus or the cytoplasm
(Table 1). We did not observe aggregates from the full-length
TDP-43-EGFP fusion protein (Fig. 2B). However, removal of the
N-terminal end of TDP-43 up to the middle of the RRM2
(constructs 2, 3 and 4) resulted in aggregates (Fig. 2A; Table 1).
Further removal of the C-terminal half of the RRM2 (construct 5)
diminished aggregation (Fig. 2B, Table 1). Similarly, removal of
the C-terminal end of TDP-43 up to the entire glycine-rich
domain (constructs 6, 7 and 8) led to aggregation (Fig. 2A; Table 1).
Further removal of RRM2 (constructs 9 and 10) abolished
aggregate formation, so did removal of both N- and C-termini
of TDP-43 (construct 11; Table 1). These observations were fully
replicated in HeLa cells (data not shown) and suggest that C-
terminal half of the RRM2 domain is necessary but not sufficient
for TDP-43 aggregation.
In general, cells transfected with the C-terminal fragments 2, 3
and 4 had a high percentage of aggregate-containing cells than the
cells transfected with the N-terminal fragments 6, 7 and 8
(Table 1). In cells where there were no aggregates, all the C-
terminal fragments were predominantly cytoplasmic while all the
N-terminal fragments were predominantly nuclear (Fig. 2B,
Table 1). This is expected based on the literature that the nuclear
localization signal is located in the N-terminal region [33].
Surprisingly, we notice that the full length construct 1 did not
show a pattern of nuclear enrichment by visualizing EGFP
fluorescence (Fig. 2B). To determine whether the EGFP signal
truly reflects the distribution of TDP-43, we examined the protein
integrity in the cell extracts using Western blot. When probed by
an anti-GFP antibody, all constructs showed a fusion protein band
(Fig. 3A). However, construct 1 also showed a strong EGFP band
at ,25 KD, indicating the EGFP signal in the cells transfected
with construct 1 largely reflects the distribution of EGFP, which
probably obscured the distribution of TDP-43-EGFP fusion
protein. How the EGFP was produced from the construct is not
clear but by immunostaining using an anti-TDP-43 antibody,
TDP-43 was predominantly nuclear in cells transfected with
Figure 1. Constructs of TDP-43 fragments. A schematic illustration of various constructs of human TDP-43 fragments. The protein domains are
marked on the top. RRM means RNA recognition motif. GRD means glycine-rich domain. The structure is not drawn in proportion. The amino acid
numbers are marked for each mutant. The red segment in construct 4 marks the C-terminal half of the RRM2 that is necessary for aggregation (see
text). For construct 8, the GRD was deleted and then the two fragments were joined together. EGFP was fused to the C-terminus of all the TDP-43
constructs.
doi:10.1371/journal.pone.0015878.g001
TDP-43 Fragments in Neuropathogenesis
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15878construct 1 (Fig. 3B), thus indicating that the TDP-43-EGFP
fusion protein is predominantly distributed in nucleus, consistent
with the literature [33,34].
TDP-43 fragments impair neurite growth in an
aggregation-dependent or independent manner
To investigate the functional consequence of TDP-43 aggrega-
tion, we examined the cell death/viability. By several assays,
including trypan blue staining, MTS assay, counting EGFP-
fluorescent cells at 1, 2 and 3 days after transfection, TUNEL,
activated caspase 3 staining and LDH release, we did not find a
significant difference among the cells transfected with the
constructs expressing EGFP and various TDP-43 fragments
(Fig. 4 and data not shown), suggesting that the TDP-43
fragments, including those that form aggregates, do not signifi-
cantly affect the viability of the cells in our culture.
To determine whether the fragmented TDP-43 impairs
neuronal characteristics, we transfected the constructs into NSC-
34 cells and then induced neuronal differentiation. The cells
transfected with full-length TDP-43-EGFP grew long neurites that
were not different from the cells transfected with EGFP (Fig. 5,
EGFP, construct 1). In contrast, cells transfected with the C-
terminal TDP-43 fragments grew short or no neurites (Fig. 5,
constructs 2–5), indicating that the C-terminal fragments impair
neurite growth. Furthermore, this impairing activity was not
dependent on TDP-43 aggregation. Both cells with aggregates
(Fig. 5A, construct 2–4 inserts) or without (Fig. 6A, constructs 2–4)
showed short or no neurites (Fig. 5B, white and black bars).
Furthermore, construct 5, which had almost no aggregates
(Table 1) and did not form any observable aggregates under the
differentiation condition, strongly impaired neurite growth (Fig. 6).
These observations indicate that aggregation is not a prerequisite
for the C-terminal fragments to impair neurite growth.
In contrast to the C-terminal fragments, the majority of cells
transfected with the N-terminal fragments or the middle fragment
grew nearly normal neurites (Fig. 5A, constructs 6-11; Fig. 5B,
white bars). However, a small number of cells that were
transfected with constructs 6, 7 and 8 displayed aggregates
(Fig 5A, constructs 6–8 inserts). In these cells, neurite growth was
impaired (Fig. 5B, black bars), suggesting that for these N-terminal
fragments the impairing activity for neurite growth depends on
their aggregation.
Figure 2. TDP-43 aggregation and distribution of non-aggre-
gated TDP-43-EGFP fragments in NSC-34 cells. (A) Examples of
cells with TDP-43 aggregates. The numbers in each row indicate the
constructs. Both nuclear (Nuc Aggr) and cytoplasmic aggregates (Cyto
Aggr) are shown. The nuclei are visualized with DAPI. The scale bar
marks 10 mm. (B) TDP-43-EGFP distribution in cells without aggregates.
The cells were transfected with the constructs: EGFP (E) and various
TDP-43-EGFP as marked on each row of panels. The cells were fixed 48
hrs after the transfection and then photographed.
doi:10.1371/journal.pone.0015878.g002
Table 1. TDP-43 aggregation in NSC34 cells.
Aggregates (%±SE)
Construct
Soluble
protein %Cells %Nuc %Cyto
Total cells
counted
1N 0
2 N/C 26.368.1 10.865.1 89.265.1 286
3 N/C 34.4691 0 . 7 63.8 89.363.8 341
4 N/C 44.668.9 4.963.7 95.163.7 347
5N / C ,1 100 ND
6N 9 . 4 60.8 2067.1 8067.1 1174
7N 9 . 4 62.4 9.960.2 90.160.2 1101
8 N 17.964.5 14.464.8 85.664.8 620
9N 0
10 N 0
11 N/C 0
Values were averages of 4 or more experiments. Distribution of soluble TDP-43
fusion proteins was determined in cells that did not contain aggregates. All
distribution was determined based on GFP signal except construct 1, which was
determined by staining for TDP-43 (see Fig. 3 and the text). Nuc means nucleus;
Cyto means cytoplasm; % transfected means the percentage of the transfected
cells detected by visualizing GFP; % nucleus means percentage of aggregate-
positive cells where the aggregates were located in the nucleus; % cytoplasm
means percent of aggregate-positive cells where the aggregates were located
in the cytoplasm; SE, standard error.
doi:10.1371/journal.pone.0015878.t001
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The TDP-43 fragments could impair neurite growth by a gain
of toxicity that is independent of the normal TDP-43 function or
by dominant negatively interfering with the normal TDP-43
function. If a gain of toxicity is true, overexpression of full length
wild type TDP-43 should not affect this toxicity. On the other
hand, if the dominant negative mechanism is true, overexpression
of the wild type TDP-43 should compensate for the functional
inhibition caused by the fragments and rescue neurite growth. To
differentiate these two possibilities, we cotransfected the full-length
TDP-43 with the TDP-43 fragments into the NSC-34 cells and
quantified the number of transfected cells with neurites (Fig. 5B,
green and red bars). The full-length TDP-43 was able to rescue the
neurite growth from the inhibition caused by TDP-43 fragments.
These results are consistent with the possibility that the TDP-43
fragments impair neurite growth by dominant negatively interfer-
ing with the normal function of TDP-43.
TDP-43 function is required for neurite growth during
neuronal differentiation
If interference of the normal function of TDP-43 caused
impairment in neurite growth, then a loss of TDP-43 function is
expected to have the same effect. To test this, we transfected NSC-
34 cells with a microRNA (miRNA)-expression construct that
silences TDP-43 expression. This construct employed the CAG
promoter to drive expression of a primary miRNA, which encode
a red fluorescent protein (dsRed2) and a pre-miRNA targeting
mouse TDP-43 (Fig. 6A) [35]. Therefore, these constructs
expressed both dsRed2 and a miRNA, which allowed us to track
the transfected cells. To control for possible non-specific effects,
such as stress associated with transfection, non-specific silencing or
non-specific cellular responses to particular miRNA sequences, we
used constructs that express two different miRNAs (miR-TDP-43a
and miR-TDP-43b) targeting different regions in mouse TDP-43
mRNA. In addition, a control construct that expresses miRNA
with scrambled sequence (miR-SCR) was used. We first tested
whether the miRNA knocked down TDP-43 by transfecting these
constructs into the NSC-34 cells. After 48 hours, we selected red-
fluorescent cells using FACS and carried out Western blot on the
protein extracted from the fluorescent cells. TDP-43 was knocked
down in cells transfected with either TDP-43-specific miRNA
compared with those cells transfected with the scrambled miRNA
(Fig. 6B). Similar to the expression of TDP-43 fragments, TDP-43
knockdown did not have a significant effect on cell death/viability
(Fig. 6C and data not shown) but significantly impaired the neurite
growth (Fig. 6D, E).
Confirmation of the observations in primary neurons
To confirm the neurite phenotype observed in NSC-34 cells, we
transfected the constructs into the rat forebrain neural precursors
and then differentiated them into neurons. The neurons
transfected with full-length TDP-43-EGFP, the N-terminal
fragments (construct 6-10) and the RRM2 fragment (construct
11) grew normal neurites that were not different from the cells
transfected with EGFP alone (Fig. 7). In contrast, cells transfected
with two C-terminal TDP-43 fragments (construct 2 and 3) grew
short or no neurites (Fig. 7). Differing from the NSC-34 cells, the
C-terminal fragments 4 and 5 and the N-terminal fragments 6, 7
and 8 did not impair neurite growth in primary neurons (Fig. 7).
This was most likely due to the relatively low transfection rate and
the low expression levels achieved in the primary neurons, where
no constructs formed aggregates. However, the two C-terminal
fragments 2 and 3 impaired the neurite growth, suggesting that
these two fragments have relatively potent toxicity.
To determine whether TDP-43 is required for neurite growth in
primary neurons, we also conducted the knockdown experiments.
Because the transfection efficiency was low, we first tested whether
our two miRNAs (which were designed to silence mouse TDP-43)
could knockdown rat TDP-43 by transfecting our constructs into
Figure 3. Expression of the various TDP-43-EGFP constructs in NSC-34 cells. (A) Forty eight hours after transfection, proteins were
extracted from NSC-34 cells and the fusion proteins were detected by Western blot using an EGFP antibody. Fifteen mg of protein was loaded in each
lane. a-Tubulin was detected as loading control. Left and right panels are two independent gels. (B) Cells was transfected with construct 1 alone and
then stained with antiTDP-43 primary and Alexa FluorH568-conjugated secondary antibodies. The nuclei are stained with DAPI. The scale bar marks
10 mm.
doi:10.1371/journal.pone.0015878.g003
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Although both miR-TDP43a and miR-TDP43b matched rat
TDP-43 mRNA sequence well, miR-TDP-43a did not knockdown
rat TDP-43 (data not shown), probably due to the sequence
differences in the regions flanking the miRNA target between the
rat and mouse TDP-43 mRNA. miR-TDP43b knocked down rat
TDP-43 efficiently (Fig. 8A). Therefore, we transfected miR-TDP-
43b and miR-SCR into the rat primary neurons and found that
neurite growth in cells transfected with miR-TDP-43b was also
significantly impaired (Fig. 8B, C). These results confirm that
TDP-43 also is required for neuronal differentiation in primary
neurons.
Fragmented TDP-43 co-aggregate with the wild type
TDP-43 and reduce nuclear TDP-43
The above data are consistent with the hypothesis that TDP-43
fragments that contain RRM2 are prone to aggregation and
impairing neurite growth by dominant-negatively interfering with
the normal TDP-43 function. The functional impairment could be
mediated through the interaction between the TDP-43 fragments
and the full-length TDP-43. To test this possibility, we
cotransfected the EGFP-tagged TDP-43 fragments with a full-
length TDP-43 that was tagged with a red fluorescent protein
tdTomato (RFP). Unlike the EGFP-tagged TDP-43, this construct
expressed the full-length fusion protein and unfused tdTomato was
detected (Fig. 9A). When cotransfected with the mutants that do
not form aggregates (Fig. 9B, constructs 5 and 11), this wild type
TDP-43 was predominantly in the nucleus with a diffused pattern.
In contrast, when cotransfected with mutants that form aggregates,
the wild type TDP-43 colocalized with the aggregates and the
diffused TDP-43 signal in the nucleus was reduced (Fig. 9B,
compare the red signal of constructs 2, 3, 4, 6, 7 and 8 with that of
constructs 5 and 11). This suggests that the TDP-43 fragments can
co-aggregate with the wild type TDP-43 and consequently deplete
the TDP-43 in the nucleus.
To determine whether the aggregation reduces the endogenous
nuclear TDP-43, we transfected the cells with the EGFP-tagged
fragments. To avoid the interference from the transfected TDP-43
fragments, we observed the endogenous TDP-43 using antibodies
against the N- or C-terminal peptide. In cells transfected with wild
type TDP-43, there was an increase in the nuclear TDP-43
staining compared with the untransfected cells (Fig. 10A, #1,
compare the nuclei pointed with filled arrowheads with those with
the open arrowheads) or EGFP-transfected cells (not shown), but
the overall ratio between the nuclear and cytoplasmic TDP-43
remained the same as the EGFP-transfected cells (Fig. 10B),
indicating that both nuclear and cytoplasmic TDP-43 are
increased to a similar extent. Similarly, in cells transfected with
a fragment that does not form aggregates (construct 11), the TDP-
43 staining intensity was the same as the untransfected cells
(Fig. 10A, #11) or EGFP-transfected cells (Fig. 10C), indicating
that this construct does not alter the nuclear and cytoplasmic
distribution of endogenous TDP-43. In contrast, in cells
transfected with the aggregation-prone fragments, the endogenous
TDP-43 was detected in the aggregates (Fig. 10A, #2, 3, 4, 6 and
7, arrows) but was reduced in the nucleus (Fig. 10A, #2, 3, 4, 6
and 7, compare the nuclei pointed with filled arrowheads with
those with open arrowheads). This observation was confirmed by
quantification of the ratio between the nuclear and cytoplasmic
staining density (Fig. 10B, C). Interestingly, in cells transfected
with the C-terminal fragments, the ratio between the nuclear and
the cytoplasmic TDP-43 was significantly reduced regardless
whether the cells had aggregates or not (Fig. 10B). On the other
hand, in cells transfected with the N-terminal fragments, this
nuclear to cytoplasmic ratio was significantly reduced in cells with
aggregates but remained unchanged in the cells without
aggregates. Thus, the reduction of nuclear TDP-43 (Fig. 10)
correlates with the inhibition of neurite growth (Fig. 5). These
results suggest that these TDP-43 fragments can co-aggregate with
the wild type TDP-43 and reduce the functional TDP-43.
Figure 4. TDP-43 fragments did not increase cell death. (A)
Caspase 3 activation was not associated with the expression of TDP-43
fragments. NSC-34 cells were transfected with the EGFP-tagged
constructs (see Fig. 1) for 72 hrs. The cells were fixed and stained for
activated caspase 3 (red). The numbers in each row indicate the
constructs. DAPI stain marks the nucleus. The scale bar represents
10 mm. Notice that cells with caspase 3 activation could be observed
(arrow) but they were not preferentially associated with the transfected
cells. (B) LDH release was not significantly elevated in NSC-34 cells
transfected with the TDP-43 fragments. Both untagged and EGFP-
tagged TDP-43 constructs were transfected into NSC34 cells for 72 hrs.
LDH activity was measured in the media and normalized to the activity
in the carrier vector transfected control cells (set at 100%). The averages
from three experiments were plotted. Error bars represent standard
deviation. The numbers along the X-axis indicate the constructs.
doi:10.1371/journal.pone.0015878.g004
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tagged fragments
To rule out the possibility that the above observations were caused
by the tags, we constructed untagged constructs and transfected them
into NSC-34 cells. Like the tagged constructs, constructs 1 (the full-
length TDP-43) and 11 did not form aggregates whereas the
aggregation-prone constructs (#2, 3 and 6) formed aggregates
(Fig. 11A). Furthermore, when cotransfected with the full-length
TDP-43,the aggregation-prone fragmentsinduced aggregationofthe
full-length TDP-43 and reduced the diffused TDP-43 staining in the
nucleus (Fig. 11B). Finally, expression of the untagged aggregation-
prone constructs impaired neurite g r o w t h( F i g .1 2 ) .T h e s er e s u l t s
confirm the observations on the tagged TDP-43 fragments.
Altering splicing is not a unifying property of the TDP-43
fragments that impaired neurite growth
A well-known function of TDP-43 is modulation of mRNA
splicing. A best characterized example is that it promotes exon 9
Figure 5. Expression of TDP-43 fragments inhibits neurite growth in motor neuron-like NSC-34 cells. (A) The cells were transfected with
EGFP and each of the TDP-43 constructs as shown in Fig. 1. The cells were also transfected with tdTomato to help visualizing neurites. Twenty-four
hours after the transfection, the cells were differentiated to neurons by serum withdraw and cultured for another 72 hours before being fixed and
photographed. (B) TDP-43-EGFP fragments were transfected with either tdTomato (white and black bars) or with the full-length TDP-43 tagged with
tdTomato (green and red bars; also see Fig. 9). Percent of cells bearing neurites were quantified and averaged from three experiments. Error bars
represent standard error. Statistics using one-factor ANOVA showed significant difference among the cells transfected with different constructs
(F=24.6, p=2610
227). Tukey’s Post Hoc Test showed significant differences comparing the EGFP-transfected cells (E) with the white bars of
constructs 2, 3, 4 and 5 and the black bars of constructs 2, 3, 4, 6, 7 and 8 with (p,0.01).
doi:10.1371/journal.pone.0015878.g005
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the TDP-43 fragments alter the spicing-modulation activity, we
assayed the CFTR splicing after transfecting various TDP-43
fragments into cultured cells. As expected, full length TDP-43
(construct 1) promoted exon 9 skipping while knockdown of TDP-
43byansiRNAinhibitedthisactivity(Fig.13).Construct3,4,5and
Figure 6. Knockdown of TDP43 inhibits neurite growth during neuronal differentiation of NSC-34 cells. (A) The miRNA expression
construct, which uses the CAG promoter to drive expression of RFP (dsRed2) and a miRNA in an intron placed in the 39-UTR of the RFP gene. The
miRNA targets mouse TDP-43. (B) Western blot of proteins extracted from the transfected NSC-34 cells. TDP-43 was knocked down in cells transfected
with two different miRNA constructs. Tubulin was detected as a loading control. miR-SCR is a scrambled miRNA that does not target any specific
genes. (C) Knockdown TDP43 does not increase cell death. Scrambled or miR-TDP43a constructs were transfected into NSC34 cells. LDH activity was
assayed in the media was 72 hrs after transfection. (D) Knockdown of TDP43 inhibits neurite growth in NSC34 cells. NSC34 cells were transfected with
the miRNA constructs. Forty-eight hours later, neuronal differentiation was initiated. After another 72 hours, the cells were fixed and visualized by
fluorescence microscopy. Scale bar represents 20 mm. (E) Quantification of cells with or without neurites. Results are shown as average percentage of
cells from three independent experiments. Error bars are standard error. Statistics using one-factor ANOVA indicated significant difference among the
cells transfected with different miRNA constructs (p=0.0001). Tukey’s Post Hoc Test showed significant differences comparing the miR-SRC-
transfected cells with the cells transfected with either miR-TDP43s (p,0.01).
doi:10.1371/journal.pone.0015878.g006
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inhibited exon 9-skipping activity (similar to TDP-43 knockdown by
siTDP43) andconstruct 6 promoted an aberrant splicing (Fig. 13). It
is notable that both constructs that interfered with the splicing
contained RRM1, suggesting that RRM1 is required for the TDP-
43 fragments to affect splicing. These results indicate that some
TDP-43 fragments are capable of altering the CFTR splicing
activity. However, this alteration is insufficient to account for the
neurite growth-impairing activity of the TDP-43 fragments.
Discussion
Our data show that both the C-terminal and the N-terminal
fragments of TDP-43 can form aggregates in mammalian cells as
long as they contain the C-terminal end of the RRM2 (Fig. 1, 2,
Table 1). The C-terminal fragments appear to have a higher
propensity for aggregation than the N-terminal fragments
(Table 1). In addition, the aggregation-prone fragments can
impair neurite growth during neuronal differentiation. However,
the N-terminal fragments impair neurite growth in an aggrega-
tion-dependent whereas the C-terminal fragments impair neurite
growth in an aggregation-independent manner (Fig. 5, 6). An
overexpression of the full-length TDP-43 rescues whereas a
knockdown of TDP-43 reproduces this impairment (Figs. 5, 7,
8). The TDP-43 fragments can co-aggregate with the full-length
TDP-43, thereby reducing TDP-43 concentration in the nucleus
(Figs. 9, 10). Although these results are initially obtained using
EGFP-tagged TDP-43 fragments, the aggregation properties and
Figure 7. Expression of TDP-43 fragments inhibits neurite growth in primary rat forebrain neurons. (A) The rat forebrain neural
precursors were transfected with EGFP and each of the TDP-43 constructs as shown in Fig. 1. The cells were also transfected with tdTomato for
visualizing neurites. Twenty-four hours after the transfection, the cells were differentiated to neurons by withdrawing basic fibroblast growth factor 2
from the medium and cultured for another 72 hours before being fixed and photographed. (B) Quantification of neurite-bearing cells as shown in (A).
Values are averages of four independent experiments. Error bars represent standard error.
doi:10.1371/journal.pone.0015878.g007
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expression of the untagged TDP-43 fragments (Fig. 11, 12). Taken
together, these results suggest a model whereby the C-terminal
fragments exert a dominant-negative toxicity on the neurons.
Consistent with this model, in FTD and ALS patients, the C-
terminal fragments are generated [18,36]. Cells in the central
nervous system (CNS) with TDP-43-positive aggregates show a
reduced nuclear TDP-43 [18]. TDP-43 function is essential for the
survival of animals and for stem cells. Gene deletion in mice and
Drosophila causes embryonic lethality [3,4,5,37,38]. Conditional
gene deletion in cultured embryonic stem cells causes cell death
[39]. Thus, a loss of functional TDP-43 to the co-aggregation with
the C-terminal fragments could cause cell degeneration and its
associated clinical symptoms.
Our result that the RRM2 is necessary for TDP-43 aggregation
agrees with the recent literature, where all fragments capable of
forming aggregates in cells contain the RRM2 region
[21,22,30,31]. The structural analysis of this region has revealed
features consistent with a high aggregation propensity. RRM2 is a
b-sheet-rich region and capable of self-association and forming
extremely stable dimers [40], reminiscent of some of the structural
features of another protein that is involved in ALS, Cu, Zn
superoxide dismutase (SOD1) [41].
The C-terminal half of TDP-43 is important for pathogenesis.
In addition to the presence of the C-terminal fragments in the
CNS tissues from the patients, most ALS-associated mutations are
located in this region [1]. It has been reported that the mutants,
either the full-length or the C-terminal fragments, have a higher
aggregation propensity than the wild type TDP-43 [29,30,42].
The C-terminal region is unstructured and involved in direct
interactions with other proteins, some of which have been
identified [6,8,43]. The N-terminal half of TDP-43 encompasses
the nuclear localization signal (NLS) and RRM1 (Fig. 1). The
latter is mainly responsible for binding RNA [44]. This N-terminal
half cannot form aggregates unless the fragment is extended to
include RRM2 (Fig. 2, Table 1). Once aggregation-enabled,
however, the N-terminal fragments can impair the neurite growth
in an aggregation-dependent manner. This suggests that the
aggregation-enabled N-terminal fragments impair neurite growth
primarily by coaggregation with the full-length TDP-43, thereby
reducing the functional TDP-43. The C-terminal fragments, on
the other hand, could impair neurite growth in at least two ways.
Similar to the N-terminal fragments, it can coaggregate with the
full-length TDP-43 and reduce the overall TDP-43 function
(Figs. 9–11). In addition, it can interact with the other partner
proteins to form non-functional complexes. Indeed, a multi-
protein complex has been isolated from cultured cells that
contained the C-terminal fragment [8]. Thus, it is conceivable
that the C-terminal fragments can impair neurite growth in an
aggregation-independent manner.
Our data indicate that the neurite growth can be an in vitro
readout for the toxicity of TDP-43 fragments. Observations from
other groups support the relevance and the reliability of this assay.
In Drosophila, a loss of TDP-43 function leads to a decrease in
dendritic branching during the development of larva nervous
system [45]. Similarly, a loss of TDP-43 function in neuro2a cells
and in zebra fish inhibited neurite growth [46,47]. Due to the
absence of the in vivo data, a role of impaired neurite growth in
Figure 8. Knockdown of TDP43 inhibits neurite growth in differentiated primary rat fore brain neurons. (A) Western blot of proteins
extracted from the transfected Rat-2 cells. TDP-43 was knocked down in cells transfected with miR-TDP43b. a-Tubulin was detected as a loading
control. (B) Knockdown of TDP43 inhibits neurite growth in rat fore brain neurons. The cells were transfected with the miRNA construct for 48 hours
and then differentiated. After another 72 hours, the cells were fixed and visualized by fluorescence microscopy. Scrambled miRNA (miR-SCR) was the
control. Scale bar represents 100 mm. (C) Quantification of cells with or without neurites. Results are shown as average percentage of cells from three
independent experiments. Error bars are standard error. Statistics using one-factor ANOVA indicated significant difference between the cells
transfected with miR-SCR and those with miR-TDP43b (p=0.00002).
doi:10.1371/journal.pone.0015878.g008
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Nevertheless, the impairment of neurite growth can be used as an
in vitro assay for further investigating the effect of a loss of TDP-43
function on neurons.
While the data from our experiments and the literature are
consistent with a dominant-negative effect of the C-terminal
fragments in neurodegeneration, this does not preclude a role from
other properties of TDP-43 in the pathogenesis. For example,
numerous studies have shown that the full-length TDP-43 can drive
aggregation and toxicitywhen TDP-43is overexpressed invitroand
in vivo [21,26,42,48,49]. Thisis not inconsistent with the dominant-
negative mechanism. Recent data hasdemonstrated that the level of
TDP-43 is tightly regulated to maintain a steady level. In
heterozygote knockout mice, where only one of the two alleles of
the TDP-43 gene actively expresses TDP-43, the mRNA and
protein levels remain unchanged [3,4,5]. Conversely, overexpres-
sion of exogenous TDP-43 down-regulates the endogenous TDP-43
[49]. The reason for this tight regulation may be understood in the
context that TDP-43 interacts with multiple protein partners to
form multiprotein complexes [6,8,43]. Either a lack of TDP-43 or
anover-abundance ofTDP-43couldformdysfunctionalcomplexes.
The lack of TDP-43 is easily understood. The over-abundance of
TDP-43 can form complexes composed of incomplete repertoire of
the protein partners dueto a limited supply of those partner protein,
leading to dysfunctional complexes. For this reason, cells may have
evolved mechanisms to ensure the proper levels of TDP-43.
Therefore, overexpression of the wild type TDP-43 could cause
dominant-negative diminution of TDP-43 function in several
different ways, e.g. driving oligomerization and aggregation,
elevatingtheproduction of the C-terminal fragmentsand increasing
the formation of non-functional complexes.
In summary, our results suggest a model where the C-terminal
fragments cause neuronal toxicity by a dominant-negative mecha-
nism. This model does not preclude a role of toxicity from the other
properties of TDP-43 protein and is consistent with the data in the
current literature. Many details in this model remain hypothetical
and will require data from experiments to confirm. Nevertheless, this
model may be a useful guide for designing future experiments.
Materials and Methods
Vectors and cloning
To construct the full-length and truncated TDP-43 tagged with
EGFP, the open reading frame (ORF) of human TDP-43 was
amplified by PCR using the forward primers with XhoI restriction
site at the 59 end and the reverse primers with BamHI restriction
site at the 59 end. The PCR product was digested with XhoI and
BamHI and inserted into the pEGFP-N1 Vector (BD Biosciences
Clontech) that was digested using the same restriction enzymes. To
construct the full-length TDP-43 tagged with tdTomato (kindly
provided by Dr. Roger Tsien [50]), the TDP-43 ORF was
amplified by PCR using the forward primer with HindIII
restriction site at its 59 end and the reverse primer with BamHI
restriction site at the 59 end. The PCR product was digested using
HindIII and BamHI and inserted upstream of the tdTomato gene,
which is in a pcDNA3.0 vector (Invitrogen). To construct the
miRNAs for silencing TDP-43, the miRNAs were designed and
generated base on the human miR-30a structure as previously
described [51]. The target sequences are 59-AAGGTGTTT-
GTTGGACGTTGT-39 for miR-TDP43a and 59-ATGCT-
GAACCTAAGCATAA-39 for miR-TDP43b. The sense and
antisense strands of DNA encoding the miRNAs were synthesized,
annealed and digested with KpnI and XhoI. They were then
cloned into an intron in the 39 untranslated region of the dsRed2
Figure 9. Coaggregation of wild type TDP-43 with its
fragments. (A) The full-length TDP-43-tdTomato construct expressed
the fusion protein. Proteins were extracted 48 hrs after the transfection
of NSC-34 cells. Fifteen mg of the protein was resolved by SDS-PAGE and
blotted. TDP-43-tdTomato was detected using a TDP43 antibody or an
HA-tag antibody. (B) The EGFP-tagged, aggregation-prone TDP-43
fragments (2, 3, 4, 6, 7 and 8) were cotransfected with the full-length
TDP-43-tdTomato construct. The full-length TDP-43 was colocalized
with all of these mutants in aggregates. Two mutants (5 and 11) that
do not form aggregates were also cotransfected with the full-length
TDP-43. In these cells, the mutants (green) were diffusely distributed
throughout the cells and the full-length wild type (red) was
predominantly in the nucleus.
doi:10.1371/journal.pone.0015878.g009
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PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e15878Figure 10. Expression of truncated TDP43 proteins reduces endogenous TDP-43 in the nucleus. NSC-34 cells were transfected with the
constructs expressing the EGFP-tagged full length and truncated TDP-43 (see Fig. 1) as indicated by the numbers in each row of panels. Seventy two
hours after the transfection, the cells were fixed and stained with antibodies against the N-terminal (for constructs 1, 2, 3, 4) or C-terminal peptides
(for constructs 6, 7 and 11) of TDP-43 to visualize the endogenous TDP-43. The cells with aggregates (green, arrows) showed reduced staining nuclear
TDP43 (red, filled arrowheads) compared with the untransfected cells (open arrowheads). Scale bar marks 10 mm. (B) Density ratio of nuclear to
cytoplasmic TDP43 in cells stained by the antibody against the N-terminus of TDP-43. The construct 4 in A was not quantified because the number of
transfected cells was too few to be reliable. (C) Density ratio of nuclear to cytoplasmic TDP43 in cells stained by the antibody against the C-terminus
of TDP-43. The ratios were normalized against the average from the cells transfected by the EGFP construct. Each bar represents values averaged
from between 18 to 28 cells. Error bars are standard error. The ratios from the cells transfected with the TDP-43 constructs were compared with the
ratio from the cells transfected with the EGFP construct using student’s t test with Bonferroni correction. The stars indicate p,0.01. Bars without stars
indicate p.0.05.
doi:10.1371/journal.pone.0015878.g010
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construct untagged TDP43, the open reading frame (ORF) of
human TDP-43 was amplified by PCR using a forward primer
with EcoRV site at the 59 end and a reverse primer with MluI site
at the 59 end. The PCR product was digested with EcoRV and
MluI and inserted into the pCAG-RFP-miR [35], replacing the
RFP. The pre-miRNA coding sequence was also removed from
this plasmid. All constructs were sequenced for verification.
Cell culture, transfection and neuronal differentiation
NSC-34 cells [32] were grown at 37uC in DMEM with 10%
FBS. The cells were then transfected with constructs using
Lipofectamine 2000 according to manufacturer’s recommenda-
tions (Invitrogen). For neuronal differentiation, twenty four (for
TDP43 and its fragments) or 72 hours (for miRNA constructs)
after transfection, the cells were transferred to wells coated with
poly-L-lysine and cultured at a density of 2610
3 cells/cm
2 in the
medium consisting of 1:1 DMEM and Ham’s F12 (Gibco BRL)
supplemented with 1% FBS, 100 U/mL penicillin, 100 mg/mL
streptomycin, and 2 mM glutamine. After 72 hrs, the cells were
fixed using 4% paraformaldehyde and 0.1% glutaraldehyde in
PBS.
For primary neuronal cultures, neural precursors were prepared
from forebrain of embryonic day 14.5 (E14.5) SASCO SD rat
Figure 11. Untagged TDP-43 fragments form aggregates and coaggregate with the full-length TDP-43. (A) Untagged TDP-43 constructs
were transfected into NSC-34 cells for 72 hrs. The cells were fixed and stained with TDP-43 (red) and tubulin (green) antibodies. The nucleus was
revealed by DAPI staining. Notice that the construct 1 (full-length) and construct 11 did not form aggregates whereas constructs 2, 3 and 6 formed
aggregates. (B) Untagged TDP-43 constructs were co-transfected with the tdTomato-tagged full-length TDP-43 for 72 hrs and then fixed. Notice that
constructs 1 and 11 did not alter the distribution of the full-length TDP-43 whereas construct 2, 3, and 6 induced aggregation of the full-length TDP-
43 and reduced the diffused staining of TDP-43 in the nucleus.
doi:10.1371/journal.pone.0015878.g011
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PLoS ONE | www.plosone.org 12 December 2010 | Volume 5 | Issue 12 | e15878Figure 12. Untagged TDP-43 impaired neurite growth during neuronal differentiation. Untagged TDP-43 constructs were cotransfected
with EGFP into NSC-34 cells for 24 hrs. The cells were differentiated for 72 hrs and fixed. Notice that cells transfected with the full-length TDP-43 grow
long neurites whereas cells transfected with constructs 2 and 3 showed impaired neurite growth regardless whether the cell had aggregates (inserts)
or not. Cells transfected with construct 6 showed impaired neurite growth only when aggregates were formed (insert).
doi:10.1371/journal.pone.0015878.g012
Figure 13. Effects of TDP43 fragments on CFTR splicing. (A) A schematic illustration of the CFTR reporter construct and its splicing products.
The large arrow represents site of the promoter, black boxes represent non-CFTR exons, the white box represent CFTR exon, and small arrows depict
primers used for amplification [53]. (B) HEK293 cells were transfected with full length or truncated TDP-43 constructs and (TG)13T3 CFTR reporter. The
reporter transcript was detected by PCR using the primers indicated in (A). Top and lower bands correspond to the complete exon 9 (the white bar in
A) inclusion and exclusion, respectively. The middle band corresponds to the splicing product from a cryptic 39 splicing site (represented by the
dashed line near the 39 end of the white bar in A). As a control, TDP43 siRNA (siTDP43) was transfected. The numbers on the top of the lane indicate
the constructs and E represents EGFP vector only.
doi:10.1371/journal.pone.0015878.g013
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at 1.2–1.4610
6 cells per 100-mm dishes precoated with 15 mg/mL
poly-L-ornithine (Sigma) and 1 mg/mL fibronectin (R&D Systems,
Minneapolis, MN), and treated daily with 10 ng/mL of basic
fibroblast growth factor 2 (FGF2) (R&D Systems). At 5 d in vitro,
cells were passaged and plated out at 0.8–1.0610
6 cells per
precoated plate and expanded as above for an additional 3–4 d
(expansion, ,300%). Cells were passaged again and plated out at
1.2–1.4610
6 per precoated plate. The cells were then transfected
with constructs using Lipofectamine 2000 (Invitrogen). Two days
after transfection, FGF2 was removed to induce neuronal
differentiation. After another 2 days, cells were washed once with
PBS and fixed.
HeLa cells (ATCC) were grown at 37uC in DMEM/10% FBS.
The cells were then transfected with constructs using Lipofecta-
mine 2000 (Invitrogen), cultured for 48 hours and then fixed.
Cell viability/death assays
NSC34 cells were transfected with different constructs and
72 hours after transfection, cell viability/death assays were
performed. Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assays were performed using the In Situ
Cell Death Detection kit, TMR red (Roche, Indianapolis)
according to the manufacturer’s instructions. The 3-(4,5-
dimethylthiazol-2-yl)-5-(3-caboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium (MTS)-based cell proliferation assay (MTS
assay) was carried out using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega, Madison, WI),
according to the manufacturer’s instructions. Absorbance at
490 nm was measured in a microplate reader (Benchmark, Bio-
Rad Laboratories, inc). After 72 hours transfection, the medium
was collected for NSC34 cells and a LDH assay (Promega) was
used to measure LDH levels as an indicator of toxicity. Cells
were then fixed and immunofluorescent staining was done using
an antibody against activated caspase-3 (1:200; Cell Signaling
Technology) and an Alexa FluorH568-conjugated goat anti-
rabbit IgG (1:400; Invitrogen).
Immunofluorescence microscopy
After fixation for 15 min at room temperature, cells were
permeabilized by using 0.5% Triton in PBS for 5 min. Nuclei
were stained with 4-, 6-diamidino-2-phenylindole (DAPI). To stain
for TDP43, the fixed cells were incubated in the blocking buffer
(5% Heat-inactivated goat serum, 0.3% Triton-X-100, 5% fat-free
dry milk in PBS, pH 7.4) for 15 min at room temperature and
then incubated with a rabbit polyclonal antibody (ProteinTech
Group, Inc, Chicago, IL) at 1:100 dilution or N- or C-terminal
rabbit polyclonal antibody (Kind gifts from Dr. Virginia Lee) at
1:1000 dilution in the blocking buffer at 4uC. After overnight
incubation, cells were washed and incubated with Alexa
FluorH568-conjugated goat anti-rabbit IgG (invitrogen) at room
temperature for 1 hour. To stain Tubulin, a mouse monoclonal
anti-a-tubulin (1:100) and Alexa FluorH488-conjugated goat anti-
mouse IgG (invitrogen) were used.
The cells were visualized and photographed using a Nikon
Eclipse Ti fluorescence microscope. For observation of nuclear
aggregates, a series of optical sections were taken along the z-axis
and processed by deconvolution (AutoQuant X, Media Cyber-
betics) to ensure that the aggregates are within the bounds of the
nucleus. For quantification of neurites, the cells with at least one
neurite longer than 10 mm in NSC-34 cells or longer than 30 mm
in primary neurons were counted as having neurites. Otherwise,
the cells were counted as having no neurites. For illustration, some
panels were adjusted for brightness and contrast as a whole.
The endogenous nuclear and cytoplasmic TDP-43 was
estimated by fluorescence density measurement. When the cells
were transfected with the full-length or the C-terminal
fragments, the antibody against the N-terminus of TDP-43 was
used for staining. When the cells were transfected with the N-
terminal fragments, the antibody against the C-terminus of
TDP-43 was used. After staining the cells were visualized and
photographed. For each cell, average density of TDP43 staining
was measured in the nucleus and the cytoplasm by Nikon NIS-
Elements software. The density ratio of the nucleus to the
cytoplasm was calculated and then normalized to the average
ratio of the EGFP control.
Immunoblotting
Cells were collected by a hard plastic cell scraper from the plates
and centrifugation at 400 g. The pellets were resuspended in
RIPA buffer (0.1% SDS, 1% Nonidet P-40, 0.5% sodium
dexoycholate, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl,
pH 8.0) plus protease inhibitors (Pierce). After clearing the lysate
by centrifugation, protein concentration of cell lysates or tissue
homogenates was measured using BCA assay (Pierce, Rockford,
IL). The samples were heated in Laemmli’s buffer, and equal
amounts of protein were loaded and resolved by SDS-PAGE.
After transfer to nitrocellulose membranes, blots were blocked
with 5% nonfat dry milk in PBST (0.25% Triton X-100 in PBS,
pH 7.4) for 1 h, and then incubated with primary antibodies
overnight. After washing 3 times in PBST, the membrane was
incubated with anti-rabbit IgG (1:5000; Amersham Biosciences) or
mouse IgG (1:5000; invitrogen) conjugated to horseradish
peroxidase for 1 hour. Membranes were washed three times and
proteins were visualized after ECL (Pierce) treatment and detected
using the LAS-3000 imaging system. The primary antibodies used
were rabbit polyclonal anti-EGFP (1:1000, Clontech) and anti-
TDP-43 (1:1000; ProteinTech Group, Inc, Chicago, IL); and
mouse monoclonal anti-a-tubulin (1:1000; Sigma) and anti-HA
(1:1000, Roche).
Analysis of CFTR mRNA splicing
The experiment was conducted based on a previously published
method [53]. Briefly, HEK293 cells were first transfected with full
length or truncated TDP-43 constructs. After 48 hrs, they were
transfected with (TG)13T3 CFTR reporter plasmid. After another
24 hrs, cells were harvested and total RNA was isolated. RT-PCR
was carried out using 5 mg of total RNA with forward A2-3 (59-
CAACTTCAAGCTCCTAAGCCACTGC-39) and reverse Bra2
(59-TAGGATCCGGTCACCAGGAAGTTGGTTAAATCA-39)
primers. PCR was performed at 95uC for 5 min, followed by 30
cycles of denaturing at 95uC for 30 s, annealing at 57uC for 30 s,
extension at 72uC for 60 s. PCR products were visualized on
agarose gels.
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